⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 26, 2008British Journal of PharmacologyOpen Access

Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspective

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

CPC E PollardAstraZeneca (United Kingdom)JVJ‐P ValentinAstraZeneca (United Kingdom)HTHammond TgAstraZeneca (United Kingdom)

Discussion

Loading...

Member takes

Implication

May refine early drug safety screening; leaves open whether combined assays better predict clinical TdP than QT alone.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pollard et al. (2008) studied this question.

synapsesocial.com/papers/6a708927f44fa9f079de3335 https://doi.org/10.1038/bjp.2008.203

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Protein trafficking abnormalities: a new mechanism in drug‐induced long QT syndrome2005 · 52 citations
2QT PRODACT: Sensitivity and Specificity of the Canine Telemetry Assay for Detecting Drug-Induced QT Interval Prolongation2005 · 32 citations
3QT PRODACT: In Vivo QT Assay With a Conscious Monkey for Assessment of the Potential for Drug-Induced QT Interval Prolongation2005 · 84 citations
4The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block2004 · 179 citations
5A structural basis for drug-induced long QT syndrome2000 · 951 citations